Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Adverum Biotechnologies and keeping the price target at $30.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Caufield has given his Buy rating due to a combination of factors related to Adverum Biotechnologies’ promising developments in their lead gene therapy candidate, Ixo-vec, for the treatment of wet age-related macular degeneration (AMD). The ongoing Phase 3 ARTEMIS trial has exceeded enrollment expectations, indicating strong interest and enthusiasm from both patients and retinal specialists. This is largely due to the potential for Ixo-vec to offer long-lasting treatment effects, possibly extending for years or even indefinitely.
Additionally, the confidence in Ixo-vec’s potential is further supported by a $10 million private placement from Frazier Life Sciences, one of the company’s largest investors. The trial’s design, which includes both treatment-naïve and previously treated wet AMD patients, reflects a broad real-world patient population, and the consistent clinical profile of Ixo-vec supports its potential success. Despite some financing challenges, the company’s ongoing discussions about prospective financing or partnerships are seen as positive steps towards the successful execution of the Phase 3 program.